An open-label, first-in-human, dose escalation study of a novel CD3-CD123 bispecific T-cell engager administered as a single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high risk myelodysplastic syndrome.

被引：4
|
作者：
Boissel, Nicolas
de Botton, Stephane
Thomas, Xavier G.
Rao, Ercole
Bonnevaux, Helene
Rubin-Carrez, Chantal
Guerif, Stephane
Beys, Eric
Gosselin, Alice
Bauchet, Anne-Laure
Novikov, Valery
Fernandes, Elma
Wiederschain, Dmitri
Palatinsky, Emanuel A.
Hsu, Karl
Fraenkel, Paula Goodman
机构：
[1] Hop St Louis, Paris, France
[2] Inst Gustave Roussy, INSERM, U1170, Villejuif, France
[3] Ctr Hosp Lyon Sud, Lyon, France
[4] Sanofi, Frankfurt, Germany
[5] Sanofi, Vitry Sur Seine, France
[6] Sanofi, Alfortville, France
[7] Sanofi, Bridgewater, NJ USA
[8] Sanofi, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS7076
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7076
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE®) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study
    Montesinos, Pau
    Arnan, Montserrat
    De Botton, Stephane
    Calbacho, Maria
    Veiga, Rebeca Rodriguez
    Bories, Pierre
    Ansoleaga, Belen
    Hueso, Thomas
    Daver, Naval
    Wunderle, Lydia
    Harstrick, Andreas
    Pietzko, Kerstin
    Hajela, Pallavi
    Vasile, Alexandra
    Witte, Tania
    Saenger, Elmarie
    Recher, Christian
    BLOOD, 2024, 144 : 739 - 739
  • [42] A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen x CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
    D'Souza, Anita
    Shah, Nina
    Rodriguez, Cesar
    Voorhees, Peter M.
    Weisel, Katja
    Bueno, Orlando F.
    Pothacamury, Rajvineeth K.
    Freise, Kevin J.
    Yue, Susan
    Ross, Jeremy A.
    Polepally, Akshanth R.
    Talati, Chetasi
    Lee, Shane
    Jin, Ziyi
    Buelow, Ben
    Vij, Ravi
    Kumar, Shaji
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (31) : 3576 - +
  • [43] Odyssey: A First-in-Human Study of the Aldehyde Dehydrogenase (ALDH) Inhibitor Abd-3001 in Patients with Refractory/Relapsed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
    Benajiba, Lina
    Colle, Julien
    Heiblig, Mael
    Loron, Sandrine
    Soret-Dulphy, Juliette
    Berchard, Paul
    Yazir, Muhube
    Basset, Laurent
    Venton, Geoffroy
    Larcher, Marie-Virginie
    De Oliveira, Rafael Daltro
    Fossard, Gaelle
    Martin, Guillaume
    Perez, Mileidys
    Ceylan, Ismael
    Pelletier, Annick
    Kiladjian, Jean-Jacques
    Costello, Regis
    BLOOD, 2024, 144 : 6001 - 6002
  • [44] A phase I/Ib open-label, first-in-human, single agent, dose escalation and expansion study of a HER2-targeted T cell engager (SAR443216) in patients with relapsed/refractory HER2-expressing solid tumors
    Dumbrava, E. E.
    Calvo, E.
    Garralda, E.
    Ryu, M. H.
    Oh, D. Y.
    Bai, L. Y.
    Chung, W.
    Rojas Laimito, K. I.
    Yildirim, O.
    Masciari, S.
    Kang, K.
    Buday, B.
    Rharbaoui, F.
    Abbadessa, G.
    Moreno Garcia, V.
    ANNALS OF ONCOLOGY, 2023, 34 : S647 - S647
  • [45] High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients
    J Pan
    J F Yang
    B P Deng
    X J Zhao
    X Zhang
    Y H Lin
    Y N Wu
    Z L Deng
    Y L Zhang
    S H Liu
    T Wu
    P H Lu
    D P Lu
    A H Chang
    C R Tong
    Leukemia, 2017, 31 : 2587 - 2593
  • [46] High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients
    Pan, J.
    Yang, J. F.
    Deng, B. P.
    Zhao, X. J.
    Zhang, X.
    Lin, Y. H.
    Wu, Y. N.
    Deng, Z. L.
    Zhang, Y. L.
    Liu, S. H.
    Wu, T.
    Lu, P. H.
    Lu, D. P.
    Chang, A. H.
    Tong, C. R.
    LEUKEMIA, 2017, 31 (12) : 2587 - 2593
  • [47] Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
    Sining Liu
    Xinyue Zhang
    Haiping Dai
    Wei Cui
    Jia Yin
    Zheng Li
    Xiao Yang
    Chunxiu Yang
    Shengli Xue
    Huiying Qiu
    Miao Miao
    Suning Chen
    Zhengming Jin
    Chengcheng Fu
    Caixia Li
    Aining Sun
    Yue Han
    Ying Wang
    Lei Yu
    Depei Wu
    Qingya Cui
    Xiaowen Tang
    Blood Cancer Journal, 13
  • [48] Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
    Liu, Sining
    Zhang, Xinyue
    Dai, Haiping
    Cui, Wei
    Yin, Jia
    Li, Zheng
    Yang, Xiao
    Yang, Chunxiu
    Xue, Shengli
    Qiu, Huiying
    Miao, Miao
    Chen, Suning
    Jin, Zhengming
    Fu, Chengcheng
    Li, Caixia
    Sun, Aining
    Han, Yue
    Wang, Ying
    Yu, Lei
    Wu, Depei
    Cui, Qingya
    Tang, Xiaowen
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [49] First-in-Human Clinical Study of a Novel CD7-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy for Refractory/Relapsed Mixed Phenotype Acute Leukemia (MPAL)
    Zhang, Xian
    Yang, Junfang
    Li, Jingjing
    Shi, Yanze
    Su, Yunchao
    Liu, Ying
    Ba, Min
    Wu, Yan
    Li, Wenqian
    Li, Jianqiang
    Lu, Peihua
    BLOOD, 2021, 138
  • [50] A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL)
    Zhang, Xian
    Wang, Jiasheng
    Liu, Yue
    Yang, Junfang
    Li, Jingjing
    Zhang, Gailing
    Shi, Yanze
    He, Jiujiang
    Song, Dan
    Li, Wenqian
    Xia, Shulian
    Zhang, Min
    Zhou, Zhixiao
    Jia, Lemei
    Zheng, Hongli
    Lin, Xin
    Lu, Peihua
    BLOOD, 2020, 136
12345